HC Wainwright Has Lowered Expectations for Vor Biopharma (NASDAQ:VOR) Stock Price

Vor Biopharma (NASDAQ:VOR) had its target price decreased by HC Wainwright from $32.00 to $31.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 95.34% from the stock’s previous close.

A number of other brokerages have also commented on VOR. JPMorgan Chase & Co. decreased their price target on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Jefferies Financial Group assumed coverage on shares of Vor Biopharma in a report on Monday, March 30th. They set a “buy” rating and a $50.00 price target for the company. Citigroup assumed coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 price target for the company. TD Cowen assumed coverage on shares of Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $50.56.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $15.87 on Wednesday. The company’s fifty day moving average price is $14.53 and its 200-day moving average price is $16.69. The firm has a market capitalization of $775.25 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80.

Insider Activity

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director directly owned 4,555,741 shares in the company, valued at $75,579,743.19. This trade represents a 11.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have sold 1,469,390 shares of company stock valued at $24,749,633. 0.45% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new position in shares of Vor Biopharma in the 4th quarter worth about $36,000. Goldman Sachs Group Inc. increased its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in Vor Biopharma during the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC bought a new stake in Vor Biopharma during the 4th quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in Vor Biopharma during the 4th quarter valued at about $134,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).